Overview

Viral Kinetics in HCV Clearance in Subjects With Hemophilia

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will examine viral dynamic responses in subjects with chronic hepatitis C and hemophilia when treated with pegylated interferon + ribavirin and telaprevir.
Phase:
Phase 1
Details
Lead Sponsor:
Kenneth Sherman
Collaborators:
Genentech, Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Vertex Pharmaceuticals Incorporated
Treatments:
Ribavirin